 | • レポートコード：MRC2304E096 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に919.41百万ドルであった世界のHIV臨床試験市場規模が、2022年に985.25百万ドルに達し、2027年には1,412.21百万ドルまで年平均7.41%で成長すると予測しています。当レポートは、HIV臨床試験の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）分析、研究デザイン別（拡大アクセス、介入、観察）分析、スポンサー別（非営利団体、製薬＆バイオ医薬品企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめています。なお、当書には、Bionor Holding AS、Charles River Laboratories、Chiltern International Ltd、Clinipace（Caidya）、Eli Lilly and Company、Gilead Sciences, Inc.、GSK plc.、ICON Plc、IQVIA Inc.、Janssen Global Services, LLCなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のHIV臨床試験市場規模：フェーズ別 - フェーズIの市場規模 - フェーズIIの市場規模 - フェーズIIIの市場規模 - フェーズIVの市場規模 ・世界のHIV臨床試験市場規模：研究デザイン別 - 拡大アクセス研究の市場規模 - 介入研究の市場規模 - 観察研究の市場規模 ・世界のHIV臨床試験市場規模：スポンサー別 - 非営利団体における市場規模 - 製薬＆バイオ医薬品企業における市場規模 ・世界のHIV臨床試験市場規模：地域別 - 南北アメリカのHIV臨床試験市場規模 アメリカのHIV臨床試験市場規模 カナダのHIV臨床試験市場規模 ブラジルのHIV臨床試験市場規模 … - アジア太平洋のHIV臨床試験市場規模 日本のHIV臨床試験市場規模 中国のHIV臨床試験市場規模 インドのHIV臨床試験市場規模 韓国のHIV臨床試験市場規模 台湾のHIV臨床試験市場規模 … - ヨーロッパ/中東/アフリカのHIV臨床試験市場規模 イギリスのHIV臨床試験市場規模 ドイツのHIV臨床試験市場規模 フランスのHIV臨床試験市場規模 ロシアのHIV臨床試験市場規模 … - その他地域のHIV臨床試験市場規模 ・競争状況 ・企業情報 |
The Global HIV Clinical Trials Market size was estimated at USD 919.41 million in 2021 and expected to reach USD 985.25 million in 2022, and is projected to grow at a CAGR 7.41% to reach USD 1,412.21 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the HIV Clinical Trials to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Phase, the market was studied across Phase I, Phase II, Phase III, and Phase IV.
Based on Study Design, the market was studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
Based on Sponsor, the market was studied across Non Profit Organizations and Pharmaceutical & Biopharmaceutical Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for HIV Clinical Trials market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the HIV Clinical Trials Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global HIV Clinical Trials Market, including Bionor Holding AS, Charles River Laboratories, Chiltern International Ltd, Clinipace (Caidya), Eli Lilly and Company, Gilead Sciences, Inc., GSK plc., ICON Plc, IQVIA Inc., Janssen Global Services, LLC, Novo Nordisk A/S, Parexel International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC, PPD Inc., PRA Health Sciences, SGS SA, Syneos Health, Inc., and Wuxi AppTec Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global HIV Clinical Trials Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global HIV Clinical Trials Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HIV Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the Global HIV Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the Global HIV Clinical Trials Market?
6. What is the market share of the leading vendors in the Global HIV Clinical Trials Market?
7. What modes and strategic moves are considered suitable for entering the Global HIV Clinical Trials Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of AIDS disease worldwide
5.1.1.2. Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
5.1.1.3. Rising governmental approvals for HIV drugs and medications
5.1.2. Restraints
5.1.2.1. High costs associated with HIV clinical trials
5.1.3. Opportunities
5.1.3.1. Advancements in HIV clinical trials solutions
5.1.3.2. Significant rise in treatment & diagnosis rate of HIV infections
5.1.4. Challenges
5.1.4.1. Less availability of healthcare infrastructures in underdeveloped countries
5.2. Cumulative Impact of COVID-19
6. HIV Clinical Trials Market, by Phase
6.1. Introduction
6.2. Phase I
6.3. Phase II
6.4. Phase III
6.5. Phase IV
7. HIV Clinical Trials Market, by Study Design
7.1. Introduction
7.2. Expanded Access Studies
7.3. Interventional Studies
7.4. Observational Studies
8. HIV Clinical Trials Market, by Sponsor
8.1. Introduction
8.2. Non Profit Organizations
8.3. Pharmaceutical & Biopharmaceutical Companies
9. Americas HIV Clinical Trials Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific HIV Clinical Trials Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa HIV Clinical Trials Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Bionor Holding AS
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Charles River Laboratories
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Chiltern International Ltd
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Clinipace (Caidya)
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Eli Lilly and Company
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Gilead Sciences, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. GSK plc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. ICON Plc
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. IQVIA Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Janssen Global Services, LLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Novo Nordisk A/S
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Parexel International Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Pfizer, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Pharmaceutical Product Development, LLC
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. PPD Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. PRA Health Sciences
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. SGS SA
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Syneos Health, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Wuxi AppTec Inc
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing